CoChat

Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan

Uchino, J, Takayama, K, Harada, A, Sone, T, Harada, T, Curiel, D T, Kuroki, M, Nakanishi, Y · 2008 · Cancer Gene Therapy

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Abstract

Irinotecan (CPT-11) is a key drug for the treatment of various cancers. CPT-11 can be considered to be a prodrug, since it needs to be activated into the toxic drug SN-38 by the enzyme carboxylesterase. However, CPT-11 may induce severe diarrhea and bone marrow suppression as adverse effects, thus leading to treatment interruption. The tumor-specific activation of CPT-11 is a possible strategy to avoid the severe toxicities by reducing the serum concentration of CPT-11. In this study, we constructed human liver carboxylesterase-2 fused with anticarcinoembryonic antigen (CEA) scFv as a targeting molecule. The recombinant enzyme anchors onto the tumor cell surface CEA, and thus metabolize CPT-11 extracellularly. In addition a secreted tumor-targeted form of carboxylesterase should help prevent the leakage of the enzyme from the site of the tumor into the circulation. This fusion protein showed CPT-11 activation to SN-38 and specific binding to CEA-expressing cells. In combination with CPT-11, the recombinant carboxylesterase protein exerted antiproliferative effects on human cancer cells. This recombinant enzyme is, therefore, a promising new tool in enzyme prodrug therapy for the treatment of carcinoma with CPT-11.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.cgt.7701100

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 21

Metadata

Authors
Uchino, J., Takayama, K., Harada, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, M., & Nakanishi, Y.
Affiliations
  • Kyushu University (JP)
  • Setsunan University (JP)
  • University of Alabama at Birmingham (US)
  • Fukuoka University (JP)
Corresponding author
Takayama, K
Venue
Cancer Gene Therapy
Published
2007-12-21
Volume
15
Issue
2
Pages
94-100
ISSN
  • 0929-1903 (ISSN-L)
  • 1476-5500
OpenAlex
W1969759353
Cited by
21
References
28
Citations by year
2023: 4 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 2 · 2013: 2 · 2012: 2
FWCI
0.25
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Cancer Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme Catalysis and Immobilization
Keywords
irinotecan, CE2, carcinoembryonic antigen, scFv, enzyme prodrug therapy, fusion protein, antiproliferative activity, drug toxicity reduction
MeSH terms
Irinotecan, Antineoplastic Agents, Phytogenic, Camptothecin, Carcinoembryonic Antigen, Dose-Response Relationship, Immunologic, HeLa Cells, Humans, Immunoglobulin Variable Region, Recombinant Fusion Proteins, Gene Targeting, Carboxylesterase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. https://app.cochat.ai/papers/10.1038/sj.cgt.7701100
The paper
Uchino, J., Takayama, K., Harada, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, M., & Nakanishi, Y. (2008). Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Cancer Gene Therapy. https://doi.org/10.1038/sj.cgt.7701100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.